NCT03190538Recruiting
Nonalcoholic Steatohepatitis in Chinese Children
Nonalcoholic Steatohepatitis in Chinese Children: a Long Term Follow-up
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
Nonalcoholic steatohepatitis (NASH) is now recognised as an increasing clinical problem in children. Steatosis without significant liver cell injury or fibrosis is the most common form of nonalcoholic fatty liver disease (NAFLD) in both adults and children. Studies in the adult population have variably suggested that steatosis is a benign nonprogressive condition and NASH is recognised as a potentially serious condition with significantly risk of morbidity and mortality. A growing body of evidence suggests that children with NASH frequently show histopathological features that differ from those of adults. The prevalence of this pattern in a wide range of paediatric cases as well as other histopathological lesions and their relevance and prognostic significance in children with NAFLD remains to be determined. Thus the investigators would like to conduct a study of biopsies and clinical information to document the histological features of paediatric NAFLD, to explore the natural history of paediatric NAFLD, and to determine the frequency and prognostic value of these features.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 10 Jun 2017
- Start date
- 1 May 2017
- Primary completion date
- 31 May 2027
- Lead sponsor
- Humanity and Health Research Centre
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT03190538
What you commit to
- Study type: Observational
- Planned participants: 400
- From 1 May 2017 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- with liver impaired by drugs
Other illness
- with viral hepatitis, e.g. HBV, HCV
- with a1-anti-trypsin disease
- with autoimmune hepatitis
- with Wilson disease
Who the study is looking for
- age 1-18 with biopsy-proven NAFLD
- Alcohol consumption less than 20g/day and 10g/day for boys and girls respectively
Age in the registry: 1 year to 18 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's Liver Disease Center, 302 Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.